Shots:

• The companies enter into a global commercialization agreement for new Prostate-Specific Membrane Antigen (PSMA) PET/CT imaging agent. GE Healthcare to take care of all pre-approval commercial preparations plus all subsequent commercial and distribution activities. Theragnostics to lead the development of the tracer- GalliProst (Gallium-68 (68Ga) diagnostic tracer) benefiting treatments for Prostate Cancer  
• The companies will utilize their combined scientific- commercial and market access expertise for the launch. The process of detecting prostate cancer will initiate with a blood test or biopsy- after which patients are referred for PET/CT imaging allowing radiologists to see the tumor- lymph nodes and any metastasis for recommending better treatments
• Theragnostics reported results of two clinical study that met its 1EPs and 2EPs showing one third of newly diagnosed prostate cancer patients and over 50% of patients with biochemically recurrent disease with 75% increment in patient management. Theragnostics’ rPARP inhibitor THG-009 (I-123 labelled PARPi) first radiopharmaceutical therapy is expected to enter in clinical development in 2020

Click here to­ read full press release/ article | Ref: NewsWire | Image: Twitter